You are here: Industry Insights > Clovis Oncology

News List

Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program firstwordpharma
August 17, 2021
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission ("SEC") to renew its previously established ATM facility under which it may offer and sell additional shares.
Clovis Oncology Appoints Ronit Simantov to its Board of Directors firstwordpharma
July 13, 2021
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the appointment of Dr. Ronit Simantov to its Board of Directors, effective today.
Clovis Oncology Highlights Rubraca (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting firstwordpharma
May 20, 2021
Clovis Oncology, today announced that four abstracts featuring data will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually, June 4-8, 2021.
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer pharmaceutical-business-review
June 17, 2020
Clovis Oncology announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP) ...
Clovis ends mid-stage trial of bladder cancer drug Rubraca citing probable lack of clinical benefit firstwordpharma
April 14, 2019
Clovis Oncology disclosed in a US Securities and Exchange Commission filing on Friday that it is discontinuing the Phase ……
Deals this week: Optinose, Kitov Pharma, Clovis Oncology pharmaceutical-technology
June 13, 2018
Optinose plans to raise funds through an initial public offering of 2.25 million shares of its common stock.
Clovis Oncology Announces European Commission Authorization of Rubraca (rucaparib) for Women with Recurrent Ovarian Cancer firstwordpharma
May 30, 2018
today announced that the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive
AstraZeneca's Lynparza, armed with new FDA nod, aims to regain share from Tesaro's Zejula fiercepharma
August 21, 2017
Lynparza, shown here in its capsule form, nabbed a new approval in pill form—and in a much bigger group of patients—weeks after setting up an $8.5 billion partnership with Merck & Co.
BMS and Clovis Oncology Enter Clinical Collaboration contractpharma
August 04, 2017
Will evaluate combination of Opdivo and Rubraca in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types
Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration worldpharmanews
August 01, 2017
Bristol-Myers Squibb Company and Clovis Oncology, Inc. announced the companies have entered into a clinical collaboration agreement to evaluate the combination of Bristol-Myers Squibb's immunotherapy Opdivo and ...

Previous page 1 2 Next page